APA (7th ed.) Citation

Lee, W., Sheehan, C., Chye, R., Chang, S., Bayes, A., Loo, C., . . . Currow, D. C. (2023). Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)—Phase II single-arm open-label feasibility study. PLoS ONE, 18(11), 1. https://doi.org/10.1371/journal.pone.0290876

Chicago Style (17th ed.) Citation

Lee, Wei, Caitlin Sheehan, Richard Chye, Sungwon Chang, Adam Bayes, Colleen Loo, Brian Draper, Meera R. Agar, and David C. Currow. "Subcutaneous Ketamine Infusion in Palliative Patients for Major Depressive Disorder (SKIPMDD)—Phase II Single-arm Open-label Feasibility Study." PLoS ONE 18, no. 11 (2023): 1. https://doi.org/10.1371/journal.pone.0290876.

MLA (9th ed.) Citation

Lee, Wei, et al. "Subcutaneous Ketamine Infusion in Palliative Patients for Major Depressive Disorder (SKIPMDD)—Phase II Single-arm Open-label Feasibility Study." PLoS ONE, vol. 18, no. 11, 2023, p. 1, https://doi.org/10.1371/journal.pone.0290876.